Bookmarks
PHOENIX DDR-Anti-PD-L1 Trial
Population Size
Not reported
Years
2019
Associated BioSamples
Availability to be confirmed
Geographic coverage
United Kingdom
England
Lead time
Other
Summary
Collection of samples and data across the following diseases: Malignant tumour of breast.
Documentation
PHOENIX DDR/Anti-PD-L1 Trial: A pre-surgical window of opportunity and post-surgical adjuvant biomarker study of DNA damage response inhibition and/or anti-PD-L1 immunotherapy in patients with neoadjuvant chemotherapy resistant residual triple negative breast cancer.
Dataset type
Health and disease
Dataset sub-type
Not applicable
Keywords
Provenance
Image contrast
Not stated
Biological sample availability
Availability to be confirmed
Details
Publishing frequency
Other
Version
1.0.0
Modified
08/10/2024
Distribution release date
17/08/2018
Citation Requirements
In Progress
Coverage
Start date
01/01/2019
Time lag
Variable
Geographic coverage
United Kingdom, England
Accessibility
Language
en
Controlled vocabulary
LOCAL
Format
In Progress
Data Access Request
Dataset pipeline status
Not available
Access rights
Please contact the publisher using Contact Point details provided.
Time to dataset access
Other
Access request cost
Not specified
Access method category
Varies based on project
Data Controller
The Institute of Cancer Research